Sequent Scientific has witnessed a major ownership restructuring as CA Hull Investments acquired a substantial 31.20% stake through the composite scheme of amalgamation that became effective on December 16, 2025. The acquisition marks a significant milestone in the company's transformation following the completion of its amalgamation with Viyash Life Sciences and other entities.

Major Stake Acquisition Details

CA Hull Investments received 13,61,60,231 equity shares of Sequent Scientific through the share exchange mechanism established under the amalgamation scheme. The acquisition was executed based on the approved share exchange ratio and has resulted in CA Hull Investments becoming part of the promoter group, while CA Harbor Investments, acting as persons in concert, holds 30.20% stake.

The acquisition was completed through allotment pursuant to the composite scheme of amalgamation involving multiple entities including Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited.

Capital Structure Transformation

The amalgamation scheme has significantly altered Sequent Scientific's capital structure, with the total equity share capital expanding substantially to accommodate the new shareholding pattern. Following the merger, CA Harbor Investments' shareholding was diluted from 52.33% pre-merger to 30.20% post-merger.

Regulatory Compliance and SEBI Disclosure

CA Hull Investments, based in Mauritius and operating through designated directors, has fulfilled all regulatory disclosure requirements under SEBI Takeover Regulations. The company filed the mandatory disclosure under Regulation 10(6) on December 17, 2025, one day after the share allotment completion. The acquisition is exempt from open offer obligations under Regulation 10(1)(d)(ii) of SEBI Takeover Regulations as it was executed through a tribunal-approved amalgamation scheme.

The acquisition represents a strategic consolidation within the pharmaceutical sector, with CA Hull Investments now holding significant influence in Sequent Scientific's operations and strategic direction. The transaction was executed without any encumbrances, pledges, or non-disposal undertakings, providing clear ownership rights to the acquiring entity. CA Hull Investments is represented by director Purnima Boyjonauth Bhogun and operates through Apex Fund Corporate Services (Mauritius) Ltd.

Sequent Scientific Limited has announced significant developments in its ongoing composite scheme of amalgamation. The company has informed the stock exchanges about two important record dates and share exchange ratios related to different aspects of the merger process.

Viyash Life Sciences and Sequent Scientific Merger

Sequent Scientific has set December 08, 2025, as the record date to determine shareholders of Viyash Life Sciences for allotment of merger consideration shares following NCLT approval of the composite amalgamation scheme. The share exchange ratio for this merger has been fixed as follows:

Viyash Life Sciences and Geninn Life Sciences Merger

In a separate but related development, Viyash Life Sciences Private Limited has set November 1, 2025, as the Record Date for determining the shareholders of Geninn Life Sciences Private Limited who will be eligible for share allotment as part of their merger process.

Composite Scheme of Amalgamation

These announcements are part of a larger composite scheme of amalgamation involving several entities, including:

• Sequent Scientific Limited
• Symed Labs Limited
• Vandana Life Sciences Private Limited
• Appcure Labs Private Limited
• Vindhya Pharma (India) Private Limited
• S.V. Labs Private Limited
• Vindhya Organics Private Limited
• Viyash Life Sciences Private Limited
• Geninn Life Sciences Private Limited
• Sequent Research Limited

Implications for Shareholders

The record dates and share exchange ratios are crucial elements in the merger process, providing clarity to the shareholders of the involved companies about their entitlement in the merged entities. These corporate actions represent significant steps in the ongoing restructuring and consolidation within the Sequent Scientific group of companies.

Investors and stakeholders of Sequent Scientific should take note of these developments as they may have implications for the company's structure and operations moving forward.